T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKI)—erlotinib and gefitinib in NSCLC patients [1–3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.